Table 1.
Patient data according to the sequence of ipilimumab (IPI) and irradiation
| IPI before irradiation (n = 20) | IPI after irradiation (n = 21) | Difference between groups (p-values) | ||
|---|---|---|---|---|
| Age (years) | ||||
| Median (range) | 62.5 | 52 | 0.28 | |
| Mean | 61 | 53 | 0.05 | |
| Sex | ||||
| Male | 70% (14) | 67% (14) | 1.00 | |
| Female | 30% (6) | 33% (7) | ||
| RPA Classification | ||||
| 3 | 40% (8) | 33% (7) | 0.66 | |
| 2 | 60% (12) | 67% (14) | ||
| 1 | 0% (0) | 0% (0) | ||
| Mode of Radiotherapy | ||||
| STX alone | 45% (9) | 29% (6) | 0.34 | |
| STX + WBRT | 15% (3) | 19% (4) | 1.00 | |
| WBRT alone | 40% (8) | 52% (11) | 0.54 | |
| Surgical resection | 15% (3) | 33% (7) | 0.24 | |
| No. of cycles of IPI | ||||
| Median (range) | 4 | 4 | 0.97 | |
| Mean | 3.5 | 3.7 | 0.72 | |
| Time interval between irradiation and IPI (months, relative to begin of irradiation) | ||||
| Median | −3 (−28; 0) | +1 (0; 21) | 0.65 | |
| Mean | 6.6 | 4 | 0.24 | |
| Further systemic therapy a | ||||
| Inhibition of MAPK signaling | BRAF inhibitor | 25% (5) | 48% (10) | 0.20 |
| MEK Inhibitor | 15% (3) | 15% (3) | 1.00 | |
| Anti PD-1/PD-L1 | 20% (4) | 15% (3) | 0.70 | |
| Conventional therapyb | 80% (16) | 81% (17) | 1.00 | |
RPA recursive partitioning analysis, MAPK mitogen-activated protein kinase, BRAF v-raf murine sarcoma viral oncogene homolog B, MEK MAPK/ERK kinase, PD-1 programmed cell death protein 1, PD-L1 programmed cell death 1 ligand 1
aSome patients received multiple treatments
bInterleukin 2, Interferon α, polychemotherapy regimens (dacarbazine, temozolomide, paclitaxel, carboplatin)